Odisha News, Odisha Latest news, Odisha Daily - OrissaPOST
  • Home
  • Trending
  • State
  • Metro
  • National
  • International
  • Business
  • Feature
  • Entertainment
  • Sports
  • More..
    • Odisha Special
    • Editorial
    • Opinion
    • Careers
    • Sci-Tech
    • Timeout
    • Horoscope
    • Today’s Pic
  • Video
  • Epaper
  • News in Odia
  • Home
  • Trending
  • State
  • Metro
  • National
  • International
  • Business
  • Feature
  • Entertainment
  • Sports
  • More..
    • Odisha Special
    • Editorial
    • Opinion
    • Careers
    • Sci-Tech
    • Timeout
    • Horoscope
    • Today’s Pic
  • Video
  • Epaper
  • News in Odia
No Result
View All Result
OrissaPOST - Odisha Latest news, English Daily -
No Result
View All Result

Good News! AstraZeneca’s antibody cocktail can treat COVID-19

Indo-Asian News Services
Updated: October 11th, 2021, 19:03 IST
in Coronavirus, Feature, International
0
AstraZeneca 3rd dose increases antibody response against Omicron
Share on FacebookShare on TwitterShare on WhatsAppShare on Linkedin

London: AstraZeneca’s long-acting antibody combination is both able to prevent and treat Covid-19, according to the phase three results released Monday.

The drug, AZD7442, is a combination of two antibodies — tixagevimab (AZD8895) and cilgavimab (AZD1061) — which is derived from B-cells donated by convalescent patients after being infected with the SARS-CoV-2 virus, the company said in a statement.

Also Read

Bangladesh violence: Properties of Awami League leaders, activists torched

14 hours ago
Manipur spurious liquor tragedy: 13 dead, 346 hospitalised in Chandel

Manipur spurious liquor tragedy: 13 dead, 346 hospitalised in Chandel

15 hours ago

The phase III trial conducted in 96 sites in Brazil, Czech Republic, Germany, Hungary, Italy, Japan, Mexico, Poland, Russian Federation, Spain, Ukraine, UK and US, included 903 participants who were administered a dose of 600mg of AZD7442 given by intramuscular (IM) injection.

The results showed that the cocktail reduced the risk of developing severe Covid-19 or death (from any cause) by 50 per cent compared to placebo in outpatients who had been symptomatic for seven days or less, the company said.

The drug was well tolerated in the trial.

“With continued cases of serious Covid-19 infections across the globe, there is a significant need for new therapies like AZD7442 that can be used to protect vulnerable populations from getting Covid-19 and can also help prevent progression to severe disease. These positive results show that a convenient intramuscular dose of AZD7442 could play an important role in helping combat this devastating pandemic,” said Hugh Montgomery, Professor of Intensive Care Medicine at University College London, in the statement.

In the participants who received treatment within five days of symptom onset, AZD7442 reduced the risk of developing severe Covid-19 or death (from any cause) by 67 per cent compared to placebo.

AZD7442 is the first cocktail with Phase III data to demonstrate benefits in both prophylaxis and treatment of Covid-19 and is easily administered by IM injection, the company said.

“An early intervention with our antibody can give a significant reduction in progression to severe disease, with continued protection for more than six months,” said Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, AstraZeneca.

AstraZeneca will be discussing the data with health authorities. The drug maker has also announced submission to the US Food and Drug Administration for Emergency Use Authorisation for AZD7442 for prophylaxis of Covid-19.

The results from the trial will also be submitted for publication in a peer-reviewed medical journal and presented at a forthcoming medical meeting, the company said.

Tags: AstraZenecaCovidCOVID deathsCovid vaccine
ShareTweetSendShare
Suggest A Correction

Enter your email to get our daily news in your inbox.

 

OrissaPOST epaper Sunday POST OrissaPOST epaper

Click Here: Plastic Free Odisha

#MyPaperBagChallenge

Pitabas Tripathy

December 12, 2019
#MyPaperBagChallenge

Akriti Negi

December 12, 2019
#MyPaperBagChallenge

Shreyanshu Bal

December 12, 2019
#MyPaperBagChallenge

Kamana Singh

December 12, 2019
#MyPaperBagChallenge

Manas Samanta

December 12, 2019
#MyPaperBagChallenge

Rajashree Manasa Mohanty

December 12, 2019
#MyPaperBagChallenge

Aishwarya Ranjan Mohanty

December 12, 2019
#MyPaperBagChallenge

Akshaya Kumar Dash

December 12, 2019
#MyPaperBagChallenge

Saishree Satyarupa

December 12, 2019
?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
#MyPaperBagChallenge

Dibya Ranjan Das

December 12, 2019
#MyPaperBagChallenge

Priyabrata Mohanty

December 12, 2019
#MyPaperBagChallenge

Praptimayee Biswal

December 12, 2019
#MyPaperBagChallenge

Diptiranjan Biswal

December 12, 2019
#MyPaperBagChallenge

Chinmay Kumar Routray

December 12, 2019
#MyPaperBagChallenge

Aman Kumar Barisal

December 12, 2019
#MyPaperBagChallenge

Adyasha Priyadarsani Sendha

December 12, 2019
#MyPaperBagChallenge

Tapaswini Mallick

December 12, 2019
#MyPaperBagChallenge

Sipra Mishra

December 12, 2019
#MyPaperBagChallenge

Debasis Mohanty

December 12, 2019
#MyPaperBagChallenge

Pragyan Priyambada

December 12, 2019
#MyPaperBagChallenge

Spinoj Pattnaik

December 12, 2019
#MyPaperBagChallenge

Sitakanta Mohanty

December 12, 2019
#MyPaperBagChallenge

Surya Sidhant Rath

December 12, 2019
#MyPaperBagChallenge

Keshab Chandra Rout

December 12, 2019
#MyPaperBagChallenge

Priyasha Pradhan

December 12, 2019
#MyPaperBagChallenge

Faiza Firdous

December 12, 2019
#MyPaperBagChallenge

Pratik Kumar

December 12, 2019
#MyPaperBagChallenge

Subhajyoti Mohanty

December 12, 2019
#MyPaperBagChallenge

Swarit Praharaj

December 12, 2019
#MyPaperBagChallenge

Bijswajit Pradhan

December 12, 2019

Archives

Editorial

Covert Shame

Aakar Patel
November 22, 2026

By Aakar Patel Murders committed by the state in India have a name: encounter. Those who carry them out are...

Read moreDetails

An Emerging Norm

November 21, 2026

By Dilip Cherian Mallika Srinivasan’s third consecutive one-year extension as chairperson of the Public Enterprises Selection Board (PESB) is increasingly...

Read moreDetails

Tech Terror

November 18, 2026

It cannot be a coincidence that when the world was still trying to come to terms with the prospect of...

Read moreDetails

More Miseries Ahead

Inflation in India
November 17, 2026

Life is getting difficult by the day for Indians with all us citizens reeling under the dual shocks of rising...

Read moreDetails
  • Home
  • State
  • Metro
  • National
  • International
  • Business
  • Editorial
  • Opinion
  • Sports
  • About Us
  • Advertise
  • Contact Us
  • Jobs
Developed By Ratna Technology

© 2025 All rights Reserved by OrissaPOST

  • News in Odia
  • Orissa POST Epaper
  • Video
  • Home
  • Trending
  • Metro
  • State
  • Odisha Special
  • National
  • International
  • Sports
  • Business
  • Editorial
  • Entertainment
  • Horoscope
  • Careers
  • Feature
  • Today’s Pic
  • Opinion
  • Sci-Tech
  • About Us
  • Contact Us
  • Jobs

© 2025 All rights Reserved by OrissaPOST

    • News in Odia
    • Orissa POST Epaper
    • Video
    • Home
    • Trending
    • Metro
    • State
    • Odisha Special
    • National
    • International
    • Sports
    • Business
    • Editorial
    • Entertainment
    • Horoscope
    • Careers
    • Feature
    • Today’s Pic
    • Opinion
    • Sci-Tech
    • About Us
    • Contact Us
    • Jobs

    © 2025 All rights Reserved by OrissaPOST